Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Charles River Laboratories disclosures can feel like running a full toxicology study—dense tables on research models, acquisition earn-outs, and animal welfare compliance stretch across hundreds of pages. If you have ever wondered, “Where can I see Charles River Laboratories insider trading Form 4 transactions before the market reacts?” you are not alone.
Stock Titan’s AI turns that complexity into clarity. Our engine delivers Charles River Laboratories SEC filings explained simply, flagging what moves the needle in real time. Whether it’s a Charles River Laboratories quarterly earnings report 10-Q filing or an 8-K on a sudden facility shutdown, you receive instant context alongside the source document.
- 10-K & 10-Q – Backlog trends, segment margins, and R&D spend with Charles River Laboratories earnings report filing analysis.
- Form 4 – Track Charles River Laboratories Form 4 insider transactions real-time to spot management’s conviction.
- Proxy (DEF 14A) – Quickly surface Charles River Laboratories proxy statement executive compensation details without scrolling through legal prose.
- 8-K – Material events such as contract wins or biosecurity updates are offered as Charles River Laboratories 8-K material events explained.
Every filing arrives within minutes of hitting EDGAR, paired with AI-powered summaries, keyword search, and historical comparisons. Use cases span monitoring Charles River Laboratories executive stock transactions Form 4, evaluating acquisition synergies, or simply understanding Charles River Laboratories SEC documents with AI. Stop wading through PDF labyrinths; start focusing on decisions that matter.
Charles River Laboratories International, Inc. reported that demand indicators in its Discovery and Safety Assessment (DSA) segment are improving. At an investor presentation at the Evercore 8th Annual Healthcare Conference, management stated that DSA net book-to-bill has improved each month since the beginning of the third fiscal quarter of 2025. The company also noted that typical holiday seasonality in the fourth quarter and early January could affect near-term proposal and booking activity, but emphasized its encouragement with the positive momentum and upward trends observed since the middle of fiscal 2025.
Charles River Laboratories International, Inc. (CRL) announced the conclusion of an SEC investigation without an enforcement recommendation. The SEC’s Division of Enforcement informed the company that, based on the information available to it, it does not intend to recommend an enforcement action related to the company’s sourcing of non-human primates and related disclosures. The company’s Audit Committee also completed its own independent investigation into the same matters, reporting no material findings. This removes a regulatory overhang that had been disclosed since May 2023.
Charles River Laboratories (CRL): Schedule 13G/A reports that Nomura Holdings, Inc. beneficially owns 807,923 shares of CRL common stock, equal to 1.6% of the class. The ownership is held with sole voting and dispositive power and is attributed to Nomura subsidiaries Nomura Global Financial Products, Inc., Nomura Securities International, Inc., and Nomura International PLC.
The percentage is based on 49,215,000 shares outstanding as of September 27, 2025. Nomura certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Charles River Laboratories (CRL): Schedule 13G/A ownership update. Wellington Management Group LLP and affiliated entities filed Amendment No. 2 reporting beneficial ownership of 3,190,467 shares of CRL common stock, representing 6.48% of the class as of the event date 09/30/2025. The filing indicates shared voting and shared dispositive power across Wellington entities, with no sole voting or dispositive power reported.
The certification states the shares were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. The securities are held of record by clients of Wellington’s advisory affiliates, and no such client is known to hold more than five percent of the class.
Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.
The filing notes these are restricted stock units with a two-step vesting schedule: 50% vest on November 6, 2026 and the remaining 50% on November 6, 2027.
Charles River Laboratories (CRL) reported Q3 2025 results. Total revenue was $1,004,852,000, slightly below last year’s $1,009,763,000. Service revenue decreased to $808,042,000, while product revenue rose to $196,810,000. Operating income increased to $133,799,000, but higher tax expense and unfavorable other income led to net income attributable to CRL of $54,422,000 versus $69,657,000 a year ago. Diluted EPS was $1.10 compared with $1.33.
By segment, Q3 revenue was: DSA $600,685,000; RMS $213,474,000; and Manufacturing $190,693,000. Operating income improved in RMS and was roughly flat in Manufacturing, while DSA softened slightly. The company changed useful lives for certain assets, reducing depreciation and increasing EPS by about $0.07 in the quarter and $0.21 year‑to‑date.
Year to date, revenue was $3,021,155,000 with diluted EPS of $2.65. Operating cash flow reached $590,126,000, funding $130,202,000 of capex and $360,577,000 of share repurchases. CRL repurchased 2.1 million shares for $350,000,000 and approved a new $1.0 billion authorization on October 29, 2025.
Charles River Laboratories International, Inc. furnished an update on its business by issuing a press release with financial results for the third quarter ended September 27, 2025. The press release was provided as Exhibit 99.1 and contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995.
The information under Item 2.02 is being furnished and is not deemed filed under the Exchange Act, except as expressly incorporated by reference in future filings.
Charles River Laboratories (CRL) Form 144 shows a proposed sale of 400 shares of common stock to be executed through UBS Financial Services on 08/22/2025 with an indicated aggregate market value of $61,000. The securities were originally acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories, with 8,379 units reported as acquired and payment in cash on 05/13/2025. The filer also reported two recent sales in August 2025: 800 shares sold on 08/18/2025 for $126,054 and 400 shares sold on 08/08/2025 for $5,991. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
